Business
Bruker Announces $500 Million Private Placement of Senior Notes to Support Strategic Growth Objectives
BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) announced today that it has completed a new private placement of 10-year senior notes
About this update from Bruker Corporation
[{"type":"text","content":" BILLERICA, Mass.--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) announced today that it has completed a new private placement of 10-year senior notes in the aggregate principal amount of $500 million to enhance its financial flexibility and fund strategic growth objectives.\n\nGerald Herman, Bruker’s Executive Vice President & Chief Financial Officer, commented “This new debt financing capitalizes on the low interest rate environment in European capital markets, locks in attractive fixed rates for the next decade, and provides Bruker with significantly expanded capacity to continue investment in our Project Accelerate 2.0 initiatives and future strategic opportunities.”\n\nUnder private placement note terms, 300 million Swiss Franc 0.88% Series A senior notes and 150 million Euro 1.03% Series B senior notes due December 8, 2031, were issued and sold to a limited number of accredited institutional investors in an offering exempt from the registration requirements of the Securities Act of 1933, as amended.\n\nBruker intends to use proceeds from this financing for general corporate purposes, including the repayment of maturing debt obligations and to support strategic growth objectives.\n\nThe new financing arrangements are subject to customary affirmative and negative covenants and other terms as detailed in a filing with the Securities and Exchange Commission on Form 8-K, dated December 8, 2021.\n\nAbout Bruker Corporation (Nasdaq: BRKR)\n\nBruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.\n\nForward Looking Statements\n\nAny statements contained in this press release which do not describe historical facts may constitute forward-looking...